Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Cedars-Sinai Medical Center
962
mi
from 98109
Los Angeles, CA
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Cedars-Sinai Medical Center
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Central Coast Medical Oncology Corporation
881
mi
from 98109
Santa Maria, CA
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Central Coast Medical Oncology Corporation
881
mi
from 98109
Santa Maria, CA
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Yale University School of Medicine
2432
mi
from 98109
New Haven, CT
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Yale University School of Medicine
2432
mi
from 98109
New Haven, CT
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Memorial Cancer Institute
2720
mi
from 98109
Hollywood, FL
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Memorial Cancer Institute
2720
mi
from 98109
Hollywood, FL
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Winship Cancer Institute Emory University School of Medicine
2178
mi
from 98109
Atlanta, GA
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Winship Cancer Institute Emory University School of Medicine
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Hope A Women's Cancer Center
2188
mi
from 98109
Asheville, NC
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Hope A Women's Cancer Center
2188
mi
from 98109
Asheville, NC
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Wake Forest University Baptist Medical Center
2275
mi
from 98109
Winston-Salem, NC
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Wake Forest University Baptist Medical Center
2275
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
University of Toledo
1927
mi
from 98109
Toledo, OH
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
University of Toledo
1927
mi
from 98109
Toledo, OH
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Central Hematology/Oncology Medical Group, Inc.
960
mi
from 98109
Alhambra, CA
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Central Hematology/Oncology Medical Group, Inc.
960
mi
from 98109
Alhambra, CA
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
St. Jude Heritage Healthcare
976
mi
from 98109
Fullerton, CA
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
St. Jude Heritage Healthcare
976
mi
from 98109
Fullerton, CA
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Wilshire Oncology Medical Group
963
mi
from 98109
La Verne, CA
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Wilshire Oncology Medical Group
963
mi
from 98109
La Verne, CA
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
University of Southern California
962
mi
from 98109
Los Angeles, CA
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
University of Southern California
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
North Valley Hematology-Oncology Medical Group
979
mi
from 98109
Northridge, CA
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
North Valley Hematology-Oncology Medical Group
979
mi
from 98109
Northridge, CA
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Ventura County Hematology Oncology Specialists
941
mi
from 98109
Oxnard, CA
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Ventura County Hematology Oncology Specialists
941
mi
from 98109
Oxnard, CA
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Florida Hospital Cancer Institute
2544
mi
from 98109
Orlando, FL
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Florida Hospital Cancer Institute
2544
mi
from 98109
Orlando, FL
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Moffitt Cancer Center
2522
mi
from 98109
Tampa, FL
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Moffitt Cancer Center
2522
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Hematology and Oncology Specialists
2091
mi
from 98109
Metairie, LA
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Hematology and Oncology Specialists
2091
mi
from 98109
Metairie, LA
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Comprehensive Cancer Centers of Nevada
885
mi
from 98109
Henderson, NV
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Comprehensive Cancer Centers of Nevada
885
mi
from 98109
Henderson, NV
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Toledo Hospital
1926
mi
from 98109
Toledo, OH
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Toledo Hospital
1926
mi
from 98109
Toledo, OH
Click here to add this to my saved trials
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated:  12/8/2015
Cross Cancer Institute
562
mi
from 98109
Edmonton,
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
Status: Enrolling
Updated: 12/8/2015
Cross Cancer Institute
562
mi
from 98109
Edmonton,
Click here to add this to my saved trials
Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors
Obesity-related Mechanisms and Mortality in Breast Cancer Survivors
Status: Enrolling
Updated:  12/8/2015
Moores UCSD Cancer Center
1053
mi
from 98109
La Jolla, CA
Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors
Obesity-related Mechanisms and Mortality in Breast Cancer Survivors
Status: Enrolling
Updated: 12/8/2015
Moores UCSD Cancer Center
1053
mi
from 98109
La Jolla, CA
Click here to add this to my saved trials
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated:  12/8/2015
Vicus Clinical Site
674
mi
from 98109
Berkeley, CA
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated: 12/8/2015
Vicus Clinical Site
674
mi
from 98109
Berkeley, CA
Click here to add this to my saved trials
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated:  12/8/2015
Vicus Clinical Site
2178
mi
from 98109
Atlanta, GA
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated: 12/8/2015
Vicus Clinical Site
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated:  12/8/2015
Vicus Clinical Site
2388
mi
from 98109
New Brunswick, NJ
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated: 12/8/2015
Vicus Clinical Site
2388
mi
from 98109
New Brunswick, NJ
Click here to add this to my saved trials
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated:  12/8/2015
Vicus Clinical Site
2393
mi
from 98109
Newark, NJ
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated: 12/8/2015
Vicus Clinical Site
2393
mi
from 98109
Newark, NJ
Click here to add this to my saved trials
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated:  12/8/2015
Vicus Clinical Site
2387
mi
from 98109
Paterson, NJ
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated: 12/8/2015
Vicus Clinical Site
2387
mi
from 98109
Paterson, NJ
Click here to add this to my saved trials
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated:  12/8/2015
Vicus Clinical Site
2110
mi
from 98109
Buffalo, NY
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated: 12/8/2015
Vicus Clinical Site
2110
mi
from 98109
Buffalo, NY
Click here to add this to my saved trials
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated:  12/8/2015
Vicus Clinical Site
2262
mi
from 98109
New York, NY
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated: 12/8/2015
Vicus Clinical Site
2262
mi
from 98109
New York, NY
Click here to add this to my saved trials
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated:  12/8/2015
Vicus Clinical Site
2373
mi
from 98109
Philadelphia, PA
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated: 12/8/2015
Vicus Clinical Site
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated:  12/8/2015
Vicus Clinical Site
1890
mi
from 98109
Houston, TX
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated: 12/8/2015
Vicus Clinical Site
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated:  12/8/2015
Vicus Clinical Site
1890
mi
from 98109
Houston, TX
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia
Status: Enrolling
Updated: 12/8/2015
Vicus Clinical Site
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/8/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2329
mi
from 98109
Baltimore, MD
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/8/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2329
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/8/2015
University of Texas, Health Science Center,Cancer Therapy and Research Center
1780
mi
from 98109
San Antonio, TX
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/8/2015
University of Texas, Health Science Center,Cancer Therapy and Research Center
1780
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/8/2015
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
1615
mi
from 98109
Madison, WI
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/8/2015
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
1615
mi
from 98109
Madison, WI
Click here to add this to my saved trials
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial
Status: Enrolling
Updated:  12/8/2015
Coleman Radiation Oncology Center
2492
mi
from 98109
Morehead City, NC
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial
Status: Enrolling
Updated: 12/8/2015
Coleman Radiation Oncology Center
2492
mi
from 98109
Morehead City, NC
Click here to add this to my saved trials
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial
Status: Enrolling
Updated:  12/8/2015
CarolinaEast Cancer Care
2463
mi
from 98109
New Bern, NC
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial
Status: Enrolling
Updated: 12/8/2015
CarolinaEast Cancer Care
2463
mi
from 98109
New Bern, NC
Click here to add this to my saved trials
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial
Status: Enrolling
Updated:  12/8/2015
South Atlantic Radiation Oncology, LLC
2449
mi
from 98109
Supply, NC
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial
Status: Enrolling
Updated: 12/8/2015
South Atlantic Radiation Oncology, LLC
2449
mi
from 98109
Supply, NC
Click here to add this to my saved trials
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial
Status: Enrolling
Updated:  12/8/2015
Coastal Carolina Radiation Oncology
2455
mi
from 98109
Wilmington, NC
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial
Status: Enrolling
Updated: 12/8/2015
Coastal Carolina Radiation Oncology
2455
mi
from 98109
Wilmington, NC
Click here to add this to my saved trials
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial
Status: Enrolling
Updated:  12/8/2015
Zimmer Cancer Center
2455
mi
from 98109
Wilmington, NC
Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial
Status: Enrolling
Updated: 12/8/2015
Zimmer Cancer Center
2455
mi
from 98109
Wilmington, NC
Click here to add this to my saved trials
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
Status: Enrolling
Updated:  12/8/2015
Georgetown University
2320
mi
from 98109
Washington D.C.,
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
Status: Enrolling
Updated: 12/8/2015
Georgetown University
2320
mi
from 98109
Washington D.C.,
Click here to add this to my saved trials
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
Status: Enrolling
Updated:  12/8/2015
University of Michigan Comprehensive Cancer Center
1903
mi
from 98109
Ann Arbor, MI
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
Status: Enrolling
Updated: 12/8/2015
University of Michigan Comprehensive Cancer Center
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of Oral CEP-37440 Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/8/2015
Teva Investigational Site 1367
1733
mi
from 98109
Chicago, IL
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of Oral CEP-37440 Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/8/2015
Teva Investigational Site 1367
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of Oral CEP-37440 Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/8/2015
Teva Investigational Site 10183
2373
mi
from 98109
Philadelphia, PA
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of Oral CEP-37440 Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/8/2015
Teva Investigational Site 10183
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of Oral CEP-37440 Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated:  12/8/2015
Teva Investigational Site
1787
mi
from 98109
San Antonio, TX
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
An Open-Label Study to Determine the Maximum Tolerated Dose of Oral CEP-37440 Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Status: Enrolling
Updated: 12/8/2015
Teva Investigational Site
1787
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)
Status: Enrolling
Updated:  12/8/2015
Western Regional Medical Center, Inc
1110
mi
from 98109
Goodyear, AZ
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)
Status: Enrolling
Updated: 12/8/2015
Western Regional Medical Center, Inc
1110
mi
from 98109
Goodyear, AZ
Click here to add this to my saved trials
Lactation Outcomes Among Survivors of Pediatric Cancer
Lactation Outcomes Among Survivors of Pediatric Cancer
Status: Enrolling
Updated:  12/8/2015
St. Jude Children's Research Hospital
1864
mi
from 98109
Memphis, TN
Lactation Outcomes Among Survivors of Pediatric Cancer
Lactation Outcomes Among Survivors of Pediatric Cancer
Status: Enrolling
Updated: 12/8/2015
St. Jude Children's Research Hospital
1864
mi
from 98109
Memphis, TN
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Helen F. Graham Cancer Center
2357
mi
from 98109
Newark, DE
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Helen F. Graham Cancer Center
2357
mi
from 98109
Newark, DE
Click here to add this to my saved trials
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated:  12/8/2015
Medical and Surgical Specialists, LLC
1634
mi
from 98109
Galesburg, IL
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60
Status: Enrolling
Updated: 12/8/2015
Medical and Surgical Specialists, LLC
1634
mi
from 98109
Galesburg, IL
Click here to add this to my saved trials